Research-grade peptide intelligence, delivered bi-weekly. Deep analysis, study breakdowns, and regulatory updates.
Survodutide Phase 2 MASH data, why the second receptor matters, and the complete 12-peptide FDA list from April 15.
Orforglipron FDA approved. Seven peptides going to advisory panel in July. Here is what both announcements actually mean.
CagriSema Phase 3 results, retatrutide TRIUMPH-4, SS-31 FDA approval, and what the Category 2 reclassification actually means.